Literature DB >> 22430405

Individuals with high-normal blood pressure have different metabolic and haemodynamic characteristics to those with optimal blood pressure.

Jacek Lewandowski1, Łukasz Artyszuk, Filip Ostrowski, Jan Ciszewski, Liana Puchalska, Piotr Abramczyk.   

Abstract

BACKGROUND: The ESH classification of blood pressure includes the high-normal blood pressure (HNBP) category, which is within normal limits but associated with increased cardiovascular (CV) risk. AIM: To identify additional CV risk factors and early signs of target organ damage in healthy individuals with HNBP.
METHODS: Healthy volunteers (n = 74) with optimal blood pressure or HNBP were compared with respect to metabolic and haemodynamic parameters.
RESULTS: The HNBP was associated with higher serum uric acid (333.1 ± 65.4 vs 267.7 ± 65.4 μmol/L, p < 0.05) and glucose (4.7 ± 0.3 vs 4.5 ± 0.3 mmol/L, p < 0.01) concentrations, intima-media thickness (0.39 ± 0.06 vs 0.36 ± 0.04 mm, p < 0.05), systemic vascular resistance index (2,678.2 ± 955.9 vs 1,930.2 ± 625.5 dyn x s x m(2)/cm(5), p < 0.001), lower total arterial compliance index (1.04 ± 0.42 vs 1.44 ± 0.48 mL/[mm Hg x m(2)], p < 0.01) and baroreflex sensitivity (14.2 ± 3.8 vs 18.0 ± 8.8 mm Hg(2)/Hz, p = 0.05).
CONCLUSIONS: The observed differences in metabolic and haemodynamic profile in HNBP may adversely affect CV risk in these individuals.

Mesh:

Substances:

Year:  2012        PMID: 22430405

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  1 in total

1.  Prevalence of hypertension mediated organ damage in subjects with high-normal blood pressure without known hypertension as well as cardiovascular and kidney disease.

Authors:  Alessandro Maloberti; Paola Rebora; Giuseppe Occhino; Marta Alloni; Francesco Musca; Oriana Belli; Francesca Spano; Gloria Maria Santambrogio; Lucia Occhi; Benedetta De Chiara; Francesca Casadei; Antonella Moreo; Maria Grazia Valsecchi; Cristina Giannattasio
Journal:  J Hum Hypertens       Date:  2021-09-07       Impact factor: 2.877

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.